Celldex Therapeutics Inc. | Small-cap | Healthcare
$22.46
2.00%
| Celldex Therapeutics Stock Comparison:
Celldex Therapeutics vs VertexCelldex Therapeutics vs RegeneronCelldex Therapeutics vs Sarepta TherapeuticsCelldex Therapeutics vs AdaptiveCelldex Therapeutics vs ArcutisCelldex Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 695.0K
Operating Income -62.7M -9,027.19%
Net Income -53.8M -7,740.43%
EPS (Diluted) $-0.81

Balance Sheet Metrics

Total Assets 739.5M
Total Liabilities 36.5M
Shareholders Equity 703.0M
Debt to Equity 0.05

Cash Flow Metrics

Operating Cash Flow -45.2M
Free Cash Flow -54.6M

Revenue & Profitability Trend

Celldex Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i7.0M6.9M2.4M4.7M7.4M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i163.6M118.0M82.3M53.3M42.5M
Selling, General & Administrative i38.5M30.9M27.2M20.5M14.5M
Other Operating Expenses i-----
Total Operating Expenses i202.1M148.9M109.5M73.8M57.0M
Operating Income i-195.1M-142.0M-107.1M-69.1M-49.6M
Operating Margin % i-2,778.9%-2,063.7%-4,543.7%-1,486.7%-668.3%
Non-Operating Items
Interest Income i-----
Interest Expense i-----
Other Non-Operating Income37.2M613.0K-5.2M-1.6M-11.4M
Pre-tax Income i-157.9M-141.4M-112.3M-70.7M-60.9M
Income Tax i-00-227.0K-1.2M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-157.9M-141.4M-112.3M-70.5M-59.8M
Net Margin % i-2,248.8%-2,054.8%-4,765.6%-1,516.0%-805.9%
Key Metrics
EBITDA i-229.1M-139.6M-99.0M-64.5M-34.3M
EPS (Basic) i$-2.45$-2.92$-2.40$-1.64$-2.02
EPS (Diluted) i$-2.45$-2.92$-2.40$-1.64$-2.02
Basic Shares Outstanding i6439500048449000468880004287000029640000
Diluted Shares Outstanding i6439500048449000468880004287000029640000

Income Statement Trend

Celldex Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i28.4M34.8M29.4M39.1M43.8M
Short-term Investments i696.9M388.8M275.5M369.1M150.6M
Accounts Receivable i700.0K2.6M347.0K172.0K1.8M
Inventory i-----
Other Current Assets21.2M5.5M12.4M2.4M1.6M
Total Current Assets i747.2M431.7M317.7M410.8M197.8M
Non-Current Assets
Property, Plant & Equipment i17.3M14.8M15.8M14.1M14.6M
Goodwill i27.2M27.2M27.2M27.2M30.7M
Intangible Assets i27.2M27.2M27.2M27.2M30.7M
Long-term Investments-----
Other Non-Current Assets-107.0K104.0K104.0K41.0K
Total Non-Current Assets i45.2M33.9M35.0M33.8M38.0M
Total Assets i792.3M465.6M352.7M444.7M235.8M
Liabilities
Current Liabilities
Accounts Payable i3.3M3.5M3.3M1.2M1.0M
Short-term Debt i1.5M1.6M1.4M1.7M1.3M
Current Portion of Long-term Debt-----
Other Current Liabilities942.0K4.0M990.0K1.6M3.4M
Total Current Liabilities i39.5M31.1M18.6M16.5M14.2M
Non-Current Liabilities
Long-term Debt i2.4M928.0K2.6M1.3M2.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities3.5M4.4M5.3M7.4M10.1M
Total Non-Current Liabilities i5.8M5.3M7.9M8.6M12.3M
Total Liabilities i45.3M36.5M26.5M25.2M26.5M
Equity
Common Stock i66.0K56.0K47.0K47.0K40.0K
Retained Earnings i-1.6B-1.4B-1.3B-1.1B-1.1B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i747.0M429.2M326.2M419.5M209.4M
Key Metrics
Total Debt i3.8M2.5M4.0M3.0M3.5M
Working Capital i707.7M400.6M299.1M394.3M183.6M

Balance Sheet Composition

Celldex Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-157.9M-141.4M-112.3M-70.5M-59.8M
Depreciation & Amortization i3.2M3.0M2.9M3.1M3.9M
Stock-Based Compensation i34.2M23.9M15.6M9.0M3.9M
Working Capital Changes i-13.3M-1.8M2.6M-2.8M-1.6M
Operating Cash Flow i-133.8M-116.4M-98.1M-63.0M-58.9M
Investing Activities
Capital Expenditures i-1.9M-1.8M-1.8M-1.2M-1.6M
Acquisitions i-----
Investment Purchases i-789.9M-424.6M-189.0M-389.9M-220.3M
Investment Sales i501.7M320.6M280.7M174.9M123.6M
Investing Cash Flow i-290.1M-105.8M89.9M-216.2M-98.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i--003.0M
Debt Repayment i--00-3.0M
Financing Cash Flow i432.3M216.2M0269.9M170.8M
Free Cash Flow i-159.7M-109.1M-105.6M-62.2M-42.0M
Net Change in Cash i8.4M-5.9M-8.2M-9.2M13.6M

Cash Flow Trend

Celldex Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -9.17
Forward P/E -6.82
Price to Book 2.23
Price to Sales 252.55
PEG Ratio -0.16

Profitability Ratios

Profit Margin 0.00%
Operating Margin -8,747.53%
Return on Equity -27.18%
Return on Assets -19.08%

Financial Health

Current Ratio 19.67
Debt to Equity 0.46
Beta 1.22

Per Share Data

EPS (TTM) $-3.01
Book Value per Share $9.87
Revenue per Share $0.09

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cldx1.5B-9.172.23-27.18%0.00%0.46
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
Sarepta Therapeutics 2.0B19.981.46-4.76%-2.34%100.51
Adaptive 2.0B-12.0411.01-57.60%-59.07%121.39
Arcutis 1.9B-13.7813.78-57.33%-35.40%79.27

Financial data is updated regularly. All figures are in the company's reporting currency.